299 related articles for article (PubMed ID: 10864227)
1. Clinical pharmacokinetics and administration of established platinum drugs.
O'Dwyer PJ; Stevenson JP; Johnson SW
Drugs; 2000; 59 Suppl 4():19-27. PubMed ID: 10864227
[TBL] [Abstract][Full Text] [Related]
2. Toxicity of platinum compounds.
Hartmann JT; Lipp HP
Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
[TBL] [Abstract][Full Text] [Related]
3. [Platinum derivatives].
Sasaki Y
Nihon Rinsho; 2004 Dec; 62 Suppl 12():452-5. PubMed ID: 15658361
[No Abstract] [Full Text] [Related]
4. Platinum compounds in children with cancer: toxicity and clinical management.
Ruggiero A; Trombatore G; Triarico S; Arena R; Ferrara P; Scalzone M; Pierri F; Riccardi R
Anticancer Drugs; 2013 Nov; 24(10):1007-19. PubMed ID: 23962902
[TBL] [Abstract][Full Text] [Related]
5. Comparative intraperitoneal pharmacokinetics of three platinum analogues.
Lind MJ; Murphy DJ; Sharma H; Tinker N; Smith A; McAuliffe CA; Crowther D
Cancer Chemother Pharmacol; 1991; 28(4):315-7. PubMed ID: 1879050
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma treatment: bypassing the toxicity of platinum compounds by using liposomal formulation and increasing treatment efficiency with concomitant radiotherapy.
Charest G; Sanche L; Fortin D; Mathieu D; Paquette B
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):244-9. PubMed ID: 22284691
[TBL] [Abstract][Full Text] [Related]
7. Characterization and cellular uptake of platinum anticancer drugs encapsulated in apoferritin.
Xing R; Wang X; Zhang C; Zhang Y; Wang Q; Yang Z; Guo Z
J Inorg Biochem; 2009 Jul; 103(7):1039-44. PubMed ID: 19501911
[TBL] [Abstract][Full Text] [Related]
8. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity.
Calvert H; Judson I; van der Vijgh WJ
Cancer Surv; 1993; 17():189-217. PubMed ID: 8137341
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.
Loh GW; Ting LS; Ensom MH
Clin Pharmacokinet; 2007; 46(6):471-94. PubMed ID: 17518507
[TBL] [Abstract][Full Text] [Related]
10. Platinum concentrations in uterus and serum after internal iliac arterial infusion of platinum compounds in rabbits.
Kigawa J; Minagawa Y; Itamochi H; Kanamori Y; Ishihara H; Terakawa N
Obstet Gynecol; 1995 Aug; 86(2):265-8. PubMed ID: 7617358
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetic properties of platinium derivatives].
Boisdron-Celle M; Lebouil A; Allain P; Gamelin E
Bull Cancer; 2001 Aug; 88 Spec No():S14-9. PubMed ID: 11567909
[TBL] [Abstract][Full Text] [Related]
12. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
Brouwers EE; Tibben MM; Rosing H; Hillebrand MJ; Joerger M; Schellens JH; Beijnen JH
J Mass Spectrom; 2006 Sep; 41(9):1186-94. PubMed ID: 16929560
[TBL] [Abstract][Full Text] [Related]
13. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
14. Platinum dose-intensity.
Los G
J Infus Chemother; 1996; 6(2):64-8. PubMed ID: 8809651
[TBL] [Abstract][Full Text] [Related]
15. Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates.
Jacobs S; McCully CL; Murphy RF; Bacher J; Balis FM; Fox E
Cancer Chemother Pharmacol; 2010 Apr; 65(5):817-24. PubMed ID: 19662415
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability].
Chatelut E
Bull Cancer; 2011 Nov; 98(11):1253-61. PubMed ID: 22024542
[TBL] [Abstract][Full Text] [Related]
17. Toxicities of the platinum antineoplastic agents.
Markman M
Expert Opin Drug Saf; 2003 Nov; 2(6):597-607. PubMed ID: 14585068
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity.
Hellberg V; Wallin I; Eriksson S; Hernlund E; Jerremalm E; Berndtsson M; Eksborg S; Arnér ES; Shoshan M; Ehrsson H; Laurell G
J Natl Cancer Inst; 2009 Jan; 101(1):37-47. PubMed ID: 19116379
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin.
Sasaki Y; Tamura T; Eguchi K; Shinkai T; Fujiwara Y; Fukuda M; Ohe Y; Bungo M; Horichi N; Niimi S
Cancer Chemother Pharmacol; 1989; 23(4):243-6. PubMed ID: 2647312
[TBL] [Abstract][Full Text] [Related]
20. Comparative adverse effect profiles of platinum drugs.
McKeage MJ
Drug Saf; 1995 Oct; 13(4):228-44. PubMed ID: 8573296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
